prednisone and Agnogenic Myeloid Metaplasia studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)."	9.19	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014)
"Thalidomide and lenalidomide can alleviate anemia in myelofibrosis."	9.14	Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009)
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia."	7.83	Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016)
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia."	7.80	[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014)
"Lenalidomide was effective in 4/7 of the patients, in some patients with no response on thalidomide."	6.46	Thalidomide and lenalidomide in primary myelofibrosis. ( de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N, 2010)
"We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment."	5.34	Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007)
"Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence)."	5.19	Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. ( Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S, 2014)
"We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL)."	5.19	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. ( Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L, 2014)
"Thalidomide and lenalidomide can alleviate anemia in myelofibrosis."	5.14	Pomalidomide is active in the treatment of anemia associated with myelofibrosis. ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009)
"This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia."	3.83	Long-term results of prednisone treatment for the anemia of myelofibrosis. ( Alvarez-Larrán, A; Barba, P; Cervantes, F; Correa, JG; Ferrer-Marín, F; García-Gutiérrez, V; Gómez, M; Hernández-Boluda, JC; Herrera, JC; Kerguelen, A; Martínez-Trillos, A; Xicoy, B, 2016)
"The purpose of the present study was to determine whether genes involved in the organization of the hematopoietic niche were dysregulated in patients with primary myelofibrosis (MF) treated with lenalidomide."	3.81	Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. ( Kusec, R; Livun, A; Manshouri, T; Newberry, KJ; Verstovsek, S, 2015)
"To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia."	3.80	[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. ( Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014)
"Lenalidomide therapy was continued indefinitely in patients exhibiting clinical benefit."	2.74	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. ( Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S, 2009)
"A 69-year-old man with agnogenic myeloid metaplasia was treated with interferon-alpha 2 as part of a Phase II clinical trial."	2.67	Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. ( Buckley, P; Duffy, TP; Radin, AI, 1991)
"Biopsy of the pharynx demonstrated follicular lymphoma which secreted large volumes of immunoglobulin M (IgM) and transforming growth factor-β (TGF-β)."	2.49	[Follicular lymphoma complicated with myelofibrosis and macroglobulinemia at initial presentation]. ( Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Murase, K; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M, 2013)
"Lenalidomide was effective in 4/7 of the patients, in some patients with no response on thalidomide."	2.46	Thalidomide and lenalidomide in primary myelofibrosis. ( de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N, 2010)
"The conventional treatment of myelofibrosis involves a wait-and-see approach for asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease, androgens or erythropoietin for the anaemia, and splenectomy in selected patients."	2.43	Modern management of myelofibrosis. ( Cervantes, F, 2005)
"Treatment with prednisone (2 mg/kg daily for 8 weeks) and vincristine (1 mg/m2 once weekly for 4 weeks) brought about partial remission of the angioimmunoblastic lymphadenopathy with normalization of the clinical and laboratory findings, the splenohepatomegaly regressed, and there was only a small amount of ascites."	2.39	[Reversible myelofibrosis in angioimmunoblastic lymphadenopathy]. ( Mayet, WJ; Meyer zum Büschenfelde, KH; Orth, T; Störkel, S; Treichel, U, 1994)
"Acute myelofibrosis (AMF), as defined by an acute panmyelopathy associated with marked megakaryocytic hyperplasia and marrow fibrosis, appears to be a stem cell disorder."	2.39	Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. ( Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS, 1996)
"Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders."	1.51	Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus. ( Belfeki, N; Declerck, D; Diamantis, S; Shankarasivam, G, 2019)
"Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder in human bone marrow."	1.46	Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis. ( Chen, X; Ding, N; Fang, X; Li, Z; Ren, L; Yang, W; Zhang, J; Zhang, P; Zhang, Y; Zhang, Z; Zhu, X, 2017)
"However, cytopenias from autoimmune myelofibrosis (AIMF) are extremely uncommon in SLE, with less than 40 reported cases in the literature."	1.43	Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. ( Chowdhary, VR; Davis, MD; Makol, A; Ungprasert, P, 2016)
"The links between myelofibrosis and autoimmunity are discussed."	1.35	[Autoimmune myelofibrosis with dermatomyositis]. ( Delfraissy, JF; Ghosn, J; Goujard, C; Lambotte, O; Lazure, T; Sahali, S, 2009)
"We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment."	1.34	Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007)
"She was also diagnosed as having a myelofibrosis with myeloid metaplasia (MMM)."	1.33	Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. ( Horii, A; Kubo, T; Mitani, K; Mizuki, M; Murata, J; Tamura, M, 2006)
"Thalidomide-based therapy has the potential to produce durable responses in MMM-associated cytopenias, even after discontinuation of the drug."	1.32	Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. ( Elliott, MA; Mesa, RA; Schroeder, G; Tefferi, A, 2004)
"A woman with scleroderma and classic polyarteritis nodosa (PAN) who developed idiopathic myelofibrosis (IM) is reported."	1.32	Idiopathic myelofibrosis associated with classic polyarteritis nodosa. ( Abelló, D; Arellano-Rodrigo, E; Camós, M; Cervantes, F; Ferrer, A; Grau, JM; Muntañola, A, 2003)
"A 46-year-old woman suffering from agnogenic myeloid metaplasia (AMM) since 1994 was being followed as an outpatient."	1.31	A pleural effusion caused by fibrous hematopoietic tumor successfully treated with prednisolone in a patient with agnogenic myeloid metaplasia with myelofibrosis. ( Hirayama, Y; Kogawa, lK; Kokai, Y; Koyama, R; Matsunaga, T; Nagai, T; Niitsu, Y; Sakamaki, S, 2002)
"A 55-year-old man with myelofibrosis was treated with natural alpha-interferon with a good hematologic response."	1.30	A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis. ( Andoh, A; Bamba, T; Fujiyama, Y; Hodohara, K; Minamiguchi, H; Nakamura, F, 1997)
"We report a case of fulminant myelofibrosis after administration of fludarabine in a patient diagnosed as having refractory low-grade lymphoma, progressing fatally."	1.30	Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. ( Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ, 1998)
"Although myelofibrosis has been described in systemic lupus erythematosus (SLE), this coexistence must be rare since there are few reports showing this combination."	1.29	Neutropenia associated with myelofibrosis in systemic lupus erythematosus. ( Borba, EF; Goncalves, CR; Pereira, IA; Pereira, RM; Velloso, ED; Yoshinari, NH, 1993)
"The patient reported here had myelofibrosis, chronic myelogenous leukemia and Sweet's syndrome."	1.29	Sweet's syndrome with myelofibrosis and leukemia: partial response to interferon. ( Brodkin, RH; Schwartz, RA, 1995)
"Primary myelofibrosis is rare in infants and children; its association with auto-immune markers has only been reported in adults."	1.29	[Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant]. ( Adam, M; Bangui, A; Leverger, G; Pilorget, H, 1996)
"A clonal cytogenetic abnormality, trisomy 8, was detected in the bone marrow cells of this child."	1.28	Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: response to corticotherapy. ( Capodano, AM; Fossat, C; Guitard, AM; Michel, G; Mozziconacci, MJ; Perrimond, H; Scheiner, C; Thuret, I, 1991)
"Extensive myelofibrosis was revealed by bone marrow biopsy."	1.28	Myelofibrosis discovered after diagnosis of Sweet's syndrome. ( Alegre, VA; Su, WP; White, WL, 1990)
"Four patients with Hodgkin's disease and bone marrow fibrosis are presented in whom the clinical presentation was dominated by cytopenias; this was associated with a delayed diagnosis for an average of 20 months."	1.28	Hodgkin's disease presenting as myelofibrosis. ( Crawford, J; Kaufman, RE; Laszlo, J; Meadows, LM; Moore, JO; Rosse, WR, 1989)
"A case of typical myelofibrosis with a huge spleen is described in a 62-year old man."	1.27	Transition of myelofibrosis to polycythaemia vera. ( Berild, D; Hasselbalch, H, 1983)
"The association of AILD and myelofibrosis has been rarely encountered and is hereby discussed."	1.27	Severe pancytopenia due to marked marrow fibrosis associated with angioimmunoblastic lymphadenopathy. ( Ben Arieh, Y; Brenner, B; Green, J; Nagler, A; Rosenbaum, H; Tatarsky, I, 1985)
"Malignant myelosclerosis or acute myelofibrosis is a rare acute myeloproliferative disorder characterized by pancytopenia, myeloblastosis and marrow fibrosis."	1.26	Malignant myelosclerosis (acute myelofibrosis): report of two cases following cytotoxic chemotherapy. ( Ali, NO; Janes, WO, 1979)

Research

Studies (84)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Number of Participants With Best Overall Response

Timeframe	Studies, this research(%)	All Research%
pre-1990	33 (39.29)	18.7374
1990's	12 (14.29)	18.2507
2000's	18 (21.43)	29.6817
2010's	19 (22.62)	24.3611
2020's	2 (2.38)	2.80

Authors	Studies
Qu, S	2
Xu, Z	2
Qin, T	2
Li, B	2
Pan, L	2
Chen, J	1
Yan, X	1
Wu, J	1
Zhang, Y	4
Zhang, P	2
Gale, RP	3
Xiao, Z	2
Mouchel, PL	1
Syrykh, C	1
Laurent, C	1
Tavitian, S	1
Gauthier, M	1
Fan, WJ	1
Wu, T	1
Chen, JW	1
Bai, H	1
Belfeki, N	1
Shankarasivam, G	1
Declerck, D	1
Diamantis, S	1
Sekiguchi, Y	1
Matsuzawa, N	1
Shimada, A	1
Imai, H	1
Wakabayashi, M	1
Sugimoto, K	1
Nakamura, N	1
Sawada, T	1
Izutsu, K	1
Takeuchi, K	1
Ohta, Y	1
Komatsu, N	1
Noguchi, M	1
Kuroda, H	1
Abe, T	1
Jomen, W	1
Yoshida, M	1
Matsuno, T	1
Sato, M	1
Yamada, M	1
Sakurai, T	1
Fujii, S	1
Maeda, M	1
Fujita, M	1
Nagashima, K	1
Murase, K	1
Kato, J	1
Tefferi, A	6
Hudgens, S	1
Mesa, R	1
Verstovsek, S	6
Passamonti, F	2
Cervantes, F	5
Rivera, C	1
Tencer, T	1
Khan, ZM	1
Rancea, M	1
Will, A	1
Borchmann, P	1
Monsef, I	1
Engert, A	1
Skoetz, N	1
Daver, N	1
Shastri, A	1
Kadia, T	1
Newberry, K	1
Pemmaraju, N	1
Jabbour, E	1
Zhou, L	1
Pierce, S	1
Cortes, J	3
Kantarjian, H	2
Xu, J	1
Fang, L	1
Zhang, H	1
Hu, N	1
Hernández-Boluda, JC	1
Martínez-Trillos, A	1
García-Gutiérrez, V	1
Ferrer-Marín, F	1
Xicoy, B	1
Alvarez-Larrán, A	1
Kerguelen, A	1
Barba, P	1
Gómez, M	1
Herrera, JC	1
Correa, JG	1
Livun, A	1
Newberry, KJ	2
Manshouri, T	2
Kusec, R	1
Ungprasert, P	1
Chowdhary, VR	1
Davis, MD	1
Makol, A	1
Chihara, D	1
Masarova, L	1
Maeng, H	1
Ravandi, F	2
Garcia-Manero, G	2
Ferrajoli, A	2
de Risi-Pugliese, T	1
Danière, F	1
Legrand, L	1
Bancel, P	1
Oppenheim, C	1
Wipff, J	1
Ding, N	1
Zhang, Z	1
Yang, W	1
Ren, L	1
Zhang, J	1
Li, Z	1
Zhu, X	1
Chen, X	1
Fang, X	1
Liu, AW	1
Bateman, AC	1
Greenbaum, A	1
Garvin, K	1
Clarridge, J	1
Grim, J	1
Sahali, S	1
Ghosn, J	1
Lazure, T	1
Goujard, C	1
Delfraissy, JF	1
Lambotte, O	1
Barosi, G	1
Roboz, GJ	1
Gisslinger, H	1
Paquette, RL	1
Rivera, CE	1
Deeg, HJ	1
Thiele, J	1
Kvasnicka, HM	1
Vardiman, JW	1
Bekele, BN	1
Mesa, RA	5
Kantarjian, HM	2
Quintás-Cardama, A	1
Thomas, D	1
Bueso-Ramos, C	1
Yao, X	1
Cripe, LD	1
Li, CY	2
Litzow, M	1
Paietta, E	1
Rowe, JM	1
Tallman, MS	1
Holle, N	1
de Witte, T	1
Mandigers, C	1
Schaap, N	1
Raymakers, R	1
Thapaliya, P	1
Pardanani, A	2
Steensma, DP	2
Camoriano, J	1
Wu, W	1
Geyer, S	1
Feld, C	1
Spangenberger, H	1
Böhm, J	1
Meuthen, D	1
Meuthen, I	1
Elliott, M	1
Kaufmann, SH	1
Wiseman, G	1
Gray, LA	1
Schroeder, G	2
Reeder, T	1
Zeldis, JB	1
Camós, M	1
Arellano-Rodrigo, E	1
Abelló, D	1
Muntañola, A	1
Ferrer, A	1
Grau, JM	1
Tsutsumi, Y	1
Tanaka, J	1
Saito, S	1
Tanaka, Y	1
Kawamura, T	1
Obara, S	1
Noto, S	1
Shimoyama, N	1
Asaka, M	1
Imamura, M	1
Masauzi, N	1
DI GUGLIELMO, R	1
CASTELLOT, JJ	1
CREVELING, RL	1
PITTS, FW	1
CHAPTAL, J	1
JEAN, R	1
IZARN, P	1
BONNET, H	1
NAVARRO, M	1
EMBERGER, JM	1
BOOTSMA, BK	1
RIECHE, K	1
MOESCHLIN, S	1
Mohren, M	1
Essbach, U	1
Franke, A	1
Klink, A	1
Maas, C	1
Markmann, I	1
Pelz, AF	1
Jentsch-Ullrich, K	1
Elliott, MA	1
Fernyhough, LJ	1
Romeril, K	1
Carter, J	1
Ritchie, DS	1
Aziz, AR	1
Mohammadian, Y	1
Ruby, C	1
Momin, Z	1
Kumar, A	1
Griciene, P	1
Gintautas, J	1
Silver, R	1
Murata, J	1
Horii, A	1
Tamura, M	1
Mitani, K	1
Mizuki, M	1
Kubo, T	1
Muslimani, A	1
Ahluwalia, MS	1
Palaparty, P	1
Daw, HA	1
Berrebi, A	1
Feldberg, E	1
Spivak, I	1
Shvidel, L	1
Domysławska, I	1
Ciołkiewicz, M	1
Kowal-Bielecka, O	1
Lewszuk, A	1
Klimiuk, PA	1
Sierakowski, S	1
Almoznino-Sarafian, D	1
Dotan, E	1
Sandbank, J	1
Gorelik, O	1
Chachashvily, S	1
Shteinshnaider, M	1
Cohen, N	1
Kueh, YK	1
Tan, YO	1
Sng, I	1
Rauff, A	1
Hasselbalch, H	1
Berild, D	1
Pegrum, GD	1
Foadi, M	1
Boots, M	1
Clarke, M	1
Krantz, S	1
Brodkin, RH	1
Schwartz, RA	1
Orth, T	1
Treichel, U	1
Mayet, WJ	1
Störkel, S	1
Meyer zum Büschenfelde, KH	1
Meerkin, D	1
Ashkenazi, Y	1
Gottschalk-Sabag, S	1
Hershko, C	1
Borba, EF	1
Pereira, RM	1
Velloso, ED	1
Pereira, IA	1
Goncalves, CR	1
Yoshinari, NH	1
Dunphy, CH	1
Kitchen, S	1
Saravia, O	1
Velasquez, WS	1
Pilorget, H	1
Bangui, A	1
Adam, M	1
Leverger, G	1
Nakamura, F	1
Andoh, A	1
Minamiguchi, H	1
Hodohara, K	1
Fujiyama, Y	1
Bamba, T	1
de las Nieves, M	1
Poveda, F	1
Queipo de Llano, MP	1
González-Hermoso, C	1
Palomera, L	1
Azaceta, G	1
Varo, MJ	1
Soria, J	1
Gutierrez, M	1
Hirayama, Y	1
Koyama, R	1
Nagai, T	1
Matsunaga, T	1
Kogawa, lK	1
Sakamaki, S	1
Kokai, Y	1
Niitsu, Y	1
Pinckney, L	1
Parker, BR	1
Ali, NO	1
Janes, WO	1
Klimova, NF	1
Heaton, A	1
Jacobs, P	1
Dent, DM	1
Louw, JH	1
Silverstein, MN	2
Radin, AI	1
Buckley, P	1
Duffy, TP	1
Michel, G	1
Thuret, I	1
Capodano, AM	1
Scheiner, C	1
Guitard, AM	1
Mozziconacci, MJ	1
Fossat, C	1
Perrimond, H	1
Su, WP	1
Alegre, VA	1
White, WL	1
Meadows, LM	1
Rosse, WR	1
Moore, JO	1
Crawford, J	1
Laszlo, J	1
Kaufman, RE	1
Macdougall, LG	1
Pettifor, JM	1
Patel, JM	1
Carroll, WL	1
Berberich, FR	1
Glader, BE	1
Brenner, B	1
Green, J	1
Rosenbaum, H	1
Ben Arieh, Y	1
Nagler, A	1
Tatarsky, I	1
Young, RC	1
Canellos, GP	1
Chabner, BA	1
Schein, PS	1
DeVita, VT	1
Perugini, S	2
Lusvarghi, E	1
Sternieri, E	1
Ferrari, G	1
Duhamel, G	1
Lévy, VG	1
Ouahnich, M	1
Gopinath, DK	1
Wolfe, RD	1
Sabharwal, K	1
Viola, MV	1
Kovi, J	1
Nukhopadhyay, M	1
Estevez, JM	1
Urueta, EE	1
Moran, TJ	1
Ascari, E	1
Fontana, G	1
Krasilnikoff, PA	1
Lee, SL	1
Rosner, F	1
Hansen, NE	1
Killmann, SA	1
Mitus, WJ	1
Coleman, N	1
Kiossoglou, KA	1
Khumbanonda, M	1
Horowitz, HI	1
Eyster, ME	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325]	Phase 2	127 participants (Actual)	Interventional	2017-02-02	Completed
A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)[NCT00946270]	Phase 2	70 participants (Actual)	Interventional	2009-07-22	Completed
Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)[NCT00352794]	Phase 2	40 participants (Actual)	Interventional	2006-07-07	Completed
A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia[NCT00227591]	Phase 2	48 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Primary endpoint is best overall response. An evaluable subject classified as a treatment success for the primary endpoint if the subject's best overall response is clinical improvement (CI) as determined by International Working Group Criteria over the first 6 cycles of study treatment. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis - Clinical improvement (CI) in anemia 1/ A minimum 20g/L increase in hemoglobin level or 2. becoming transfusion independent for at least 8 week duration. (NCT00946270)
Timeframe: 6 months

Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement)

Intervention	Participants (Count of Participants)
Group 1 CC-4047	0
Group 2	3
Group 3 CC-4047 + Prednisone	6

Time to response defined as the time from start of therapy until the response criteria are fulfilled. Response duration defined as the time from response until relapse (progressive disease) or death. (NCT00352794)
Timeframe: 6 months

Overall Response Rate

Intervention	Participants (Count of Participants)
Lenalidomide + Prednisone	14

"Response was evaluated for Anemia and Spleen:~Major anemia response: hemoglobin increase to within normal limits in the absence of transfusion. Minor anemia response: hemoglobin improvement of at least 2 grams per deciliter independent of transfusion support, or achievement of transfusion independence in transfusion-dependent patients. Major spleen response: normalization of spleen size to the range of 12-14 centimeters by ultrasound. Minor spleen response: a 50% or more decrease in excess spleen size by ultrasound. Complete remission (CR): complete resolution of disease-related symptoms, splenomegaly, normalization of peripheral blood count, white cell differential and smear, and normalization of bone marrow histology. Partial remission (PR): a major or minor response in anemia or splenomegaly. Overall Response (OR)=CR + PR, assessed among eligible, treated patients." (NCT00227591)
Timeframe: Assessed at the end of cycle 3

Article	Year
[Research and Applications Progress of Lenalidomide for Myelofibrosis--Review]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:6 Topics: Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide	2018
Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature. International journal of hematology, 2013, Volume: 98, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Cytokines; Doxo	2013
[Follicular lymphoma complicated with myelofibrosis and macroglobulinemia at initial presentation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:11 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha	2013
Thalidomide and lenalidomide in primary myelofibrosis. The Netherlands journal of medicine, 2010, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Hematopoiesis; Huma	2010
Modern management of myelofibrosis. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Adult; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Humans; Middle Aged; Palliative Care; Pred	2005
[Reversible myelofibrosis in angioimmunoblastic lymphadenopathy]. Deutsche medizinische Wochenschrift (1946), 1994, May-13, Volume: 119, Issue:19 Topics: Biopsy, Needle; Bone Marrow; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopath	1994
Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia. Cancer, 1994, Feb-01, Volume: 73, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Diffe	1994
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. American journal of hematology, 1996, Volume: 51, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro	1996
[Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases]. La Clinica terapeutica, 1968, Apr-15, Volume: 45, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Androgens; Anemia; Busulfan; Drug Synergism; Female; Humans; Leukocy	1968

Article	Year
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clinical therapeutics, 2014, Apr-01, Volume: 36, Issue:4 Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferativ	2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia research, 2014, Volume: 38, Issue:9 Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Hu	2014
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia research, 2016, Volume: 48 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St	2016
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27 Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Hu	2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Lin	2009
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood, 2010, Nov-25, Volume: 116, Issue:22 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Le	2010
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 2003, Apr-01, Volume: 101, Issue:7 Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Ant	2003
Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. Hematologic pathology, 1991, Volume: 5, Issue:2 Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Anti-Idiotypic; Autoantibodies; Blood Transfusion;	1991
Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet (London, England), 1973, Jun-16, Volume: 1, Issue:7816 Topics: Blood Cell Count; Blood Platelets; Hodgkin Disease; Humans; Lymphocytes; Mechlorethamine; Nitrosoure	1973

Article	Year
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological oncology, 2022, Volume: 40, Issue:4 Topics: Anemia; Danazol; Hemoglobins; Humans; Myeloproliferative Disorders; Nitriles; Pilot Projects; Predni	2022
First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; DNA, Viral	2021
Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus. BMJ case reports, 2019, Jan-14, Volume: 12, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Antirheumatic Agents; Autoimmune Disease	2019
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine	2014
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:8 Topics: Adult; Aged; Anemia; Danazol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mi	2014
Long-term results of prednisone treatment for the anemia of myelofibrosis. Leukemia & lymphoma, 2016, Volume: 57, Issue:1 Topics: Aged; Anemia; Anti-Inflammatory Agents; Bone Marrow; Erythrocyte Indices; Female; Humans; Immunosupp	2016
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer research, 2015, Volume: 35, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Clinical Trials, Phase II as T	2015
Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus, 2016, Volume: 25, Issue:4 Topics: Adult; Autoimmune Diseases; Biopsy; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus	2016
Extramedullary hematopoiesis with spinal cord compression in pachydermoperiostosis. Joint bone spine, 2017, Volume: 84, Issue:4 Topics: Adult; Decompression, Surgical; Follow-Up Studies; Hematopoiesis, Extramedullary; Humans; Laminectom	2017
Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis. Genomics, proteomics & bioinformatics, 2017, Volume: 15, Issue:1 Topics: Androgens; Bone Marrow; Child, Preschool; Chromosomes, Human, Pair 19; Cytogenetic Analysis; Gene Ex	2017
Cutaneous phaeohyphomycosis in a hematopoietic stem cell transplant patient caused by Alternaria rosae: First case report. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3 Topics: Acute Kidney Injury; Acyclovir; Aged; Alternaria; Alternariosis; Antibiotic Prophylaxis; Antifungal	2017
[Autoimmune myelofibrosis with dermatomyositis]. La Revue de medecine interne, 2009, Volume: 30, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Autoimmune Diseases; Biopsy; Dermatologic Agents; Dermatomyositis;	2009
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Male; Middle Aged; Prednisone; Primary Myel	2011
[76-year old patient with suspected but not confirmed "idiopathic myelofibrosis"]. Der Internist, 2011, Volume: 52, Issue:11 Topics: Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Male; Mastocytosis; Prednisone; Pri	2011
Idiopathic myelofibrosis associated with classic polyarteritis nodosa. Leukemia & lymphoma, 2003, Volume: 44, Issue:3 Topics: Abdominal Pain; Autoimmune Diseases; Cyclophosphamide; Diagnostic Errors; Fatal Outcome; Female; Hum	2003
Myelofibrosis after essential thrombocythemia complicated by alveolar proteinosis. Leukemia & lymphoma, 2003, Volume: 44, Issue:6 Topics: Bone Marrow; Fatal Outcome; Female; Humans; Lung; Middle Aged; Prednisone; Primary Myelofibrosis; Pu	2003
[Nosologico-therapeutic notes on osteomyelofibrosis]. Giornale di gerontologia, 1960, Volume: 8 Topics: Humans; Osteomyelitis; Prednisone; Primary Myelofibrosis	1960
Fatal miliary coccidioidomycosis complicating prolonged prednisone therapy in a patient with myelofibrosis. Annals of internal medicine, 1960, Volume: 52 Topics: Bone Marrow; Bone Marrow Diseases; Coccidioidomycosis; Humans; Prednisone; Primary Myelofibrosis	1960
[CHRONIC MYELOID LEUKOSIS IN CHILDREN: 4 CASES]. Pediatrie, 1963, Volume: 18 Topics: Blood Platelet Disorders; Busulfan; Child; Humans; Leukemia; Leukemia, Myeloid; Leukocytosis; Lymph	1963
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II]. Nederlands militair geneeskundig tijdschrift, 1964, Volume: 17 Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X-	1964
[DATA TO THE DIAGNOSTIC VALUE OF FIBRINOGEN DETERMINATION IN MALIGNANT DISEASES]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1964, Aug-15, Volume: 19 Topics: Cyclophosphamide; Fibrinogen; Hodgkin Disease; Humans; Metaplasia; Myeloproliferative Disorders; Neo	1964
[MODERN TREATMENT OF LEUKEMIA]. Schweizerische medizinische Wochenschrift, 1965, Feb-13, Volume: 95 Topics: Agranulocytosis; Busulfan; Chlorambucil; Cyclophosphamide; Drug Therapy; Genetic Diseases, X-Linked;	1965
Acute myelofibrosis in a patient with diffuse large cell non Hodgkin's lymphoma and renal cancer. Leukemia & lymphoma, 2003, Volume: 44, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Chromosome Aberr	2003
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clinic proceedings, 2004, Volume: 79, Issue:7 Topics: Adult; Aged; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Pr	2004
Marrow fibrosis and pure red cell aplasia complicating early stage chronic lymphocytic leukaemia. Pathology, 2005, Volume: 37, Issue:2 Topics: Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Midd	2005
Systemic lupus erythematosus presenting with pancytopenia due to bone marrow myelofibrosis in a 22-year-old male. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:7 Topics: Adult; Bone Marrow; Epistaxis; Glomerulonephritis, Membranous; Humans; Immunosuppressive Agents; Lup	2004
Current treatment of myelofibrosis. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:4 Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Man	2005
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. Acta oto-laryngologica, 2006, Volume: 126, Issue:5 Topics: Acute Disease; Audiometry, Evoked Response; Autoimmune Diseases; C-Reactive Protein; Diagnosis, Diff	2006
Idiopathic myelofibrosis associated with dermatomyositis. American journal of hematology, 2006, Volume: 81, Issue:7 Topics: Anti-Inflammatory Agents; Dermatomyositis; Female; Humans; Middle Aged; Prednisone; Primary Myelofib	2006
Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. Haematologica, 2007, Volume: 92, Issue:2 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Bone Marrow; Combined Modality Therap	2007
[Coexistence of scleroderma-like syndrome and idiopathic myelofibrosis in a 54-year-old female patient: case report]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:8 Topics: Antineoplastic Agents; Azathioprine; Female; Glucocorticoids; Humans; Hydroxyurea; Immunosuppressive	2007
Unusual manifestations of myelofibrosis in a patient with congenital asplenia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Adult; Anti-Bacterial Agents; Bone Diseases, Metabolic; Disease Susceptibility; Erythema Nodosum; Fe	2007
Reversal of red cell aplasia and marrow fibrosis in non-Hodgkin's lymphoma. Annals of the Academy of Medicine, Singapore, 1983, Volume: 12, Issue:3 Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; L	1983
Transition of myelofibrosis to polycythaemia vera. Scandinavian journal of haematology, 1983, Volume: 30, Issue:2 Topics: Anemia, Hemolytic, Autoimmune; Hematopoiesis; Hepatomegaly; Humans; Male; Middle Aged; Polycythemia	1983
How should we manage myelofibrosis? Journal of the Royal College of Physicians of London, 1981, Volume: 15, Issue:1 Topics: Blood Transfusion; Chlorambucil; Humans; Prednisone; Primary Myelofibrosis; Splenectomy	1981
Anemia due to bone marrow failure: diagnosis and treatment. Comprehensive therapy, 1980, Volume: 6, Issue:7 Topics: Aged; Anemia, Aplastic; Anemia, Sideroblastic; Animals; Bone Marrow; Cyclophosphamide; Erythropoiesi	1980
Sweet's syndrome with myelofibrosis and leukemia: partial response to interferon. Dermatology (Basel, Switzerland), 1995, Volume: 190, Issue:2 Topics: Aged; Facial Dermatoses; Hand Dermatoses; Humans; Injections, Intralesional; Interferon-alpha; Leuke	1995
Neutropenia associated with myelofibrosis in systemic lupus erythematosus. Acta haematologica, 1993, Volume: 89, Issue:2 Topics: Adult; Biopsy; Bone Marrow; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Lupus Erythe	1993
[Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1996, Volume: 3, Issue:1 Topics: Combined Modality Therapy; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Infant; Pr	1996
A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis. Acta haematologica, 1997, Volume: 97, Issue:4 Topics: Anti-Inflammatory Agents; Humans; Immunologic Factors; Interferon-alpha; Lung Diseases, Interstitial	1997
[System mastocytosis: presentation of a case evolving into myelofibrosis and no response to interferon alfa 2b]. Sangre, 1997, Volume: 42, Issue:5 Topics: Bone Marrow; Cerebral Hemorrhage; Combined Modality Therapy; Fatal Outcome; Female; Histamine Antago	1997
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma. Haematologica, 1998, Volume: 83, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D	1998
A pleural effusion caused by fibrous hematopoietic tumor successfully treated with prednisolone in a patient with agnogenic myeloid metaplasia with myelofibrosis. International journal of hematology, 2002, Volume: 75, Issue:3 Topics: Anti-Inflammatory Agents; Cytokines; Female; Humans; Middle Aged; Pleural Effusion; Prednisone; Prim	2002
Myelosclerosis and myelofibrosis in treated histiocytosis-X. AJR. American journal of roentgenology, 1977, Volume: 129, Issue:3 Topics: Fractures, Spontaneous; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Prednisone; Primary My	1977
Malignant myelosclerosis (acute myelofibrosis): report of two cases following cytotoxic chemotherapy. Cancer, 1979, Volume: 43, Issue:4 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Glom	1979
[10-years experience with myelobromol treatment of myelofibrosis]. Haematologia, 1977, Volume: 11, Issue:1-2 Topics: Blood Transfusion; Hematopoiesis; Hepatomegaly; Humans; Mannitol; Mitobronitol; Pancytopenia; Polycy	1977
Experience with splenectomy in auto-immune thrombocytopenia and agnogenic myeloid metaplasia. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1976, Sep-11, Volume: 50, Issue:39 Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Female; Hemorrhage; Humans; Infections; Male; Middle A	1976
The evolution into and the treatment of late stage polycythemia vera. Seminars in hematology, 1976, Volume: 13, Issue:1 Topics: Anemia; Female; Humans; Iron; Male; Phosphorus Radioisotopes; Polycythemia Vera; Prednisone; Primary	1976
Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: response to corticotherapy. Medical and pediatric oncology, 1991, Volume: 19, Issue:1 Topics: Child; Chromosomes, Human, Pair 8; Eosinophilia; Female; Humans; Leukocyte Count; Prednisone; Primar	1991
Myelofibrosis discovered after diagnosis of Sweet's syndrome. International journal of dermatology, 1990, Volume: 29, Issue:3 Topics: Adult; Fever; Humans; Male; Neutrophils; Prednisone; Primary Myelofibrosis; Skin Diseases; Syndrome	1990
Hodgkin's disease presenting as myelofibrosis. Cancer, 1989, Oct-15, Volume: 64, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diagnosis, Differential; Female;	1989
Bone growth and haemopoiesis: steroid reversible anaemia, myelofibrosis and increased bone formation in a child. British journal of haematology, 1987, Volume: 66, Issue:1 Topics: Anemia, Aplastic; Bone Diseases, Developmental; Child, Preschool; Hematopoiesis; Humans; Ilium; Male	1987
Pancytopenia with myelofibrosis. An unusual presentation of childhood Hodgkin's disease. Clinical pediatrics, 1986, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Female; Hodgkin Disease; Humans;	1986
Severe pancytopenia due to marked marrow fibrosis associated with angioimmunoblastic lymphadenopathy. Acta haematologica, 1985, Volume: 74, Issue:1 Topics: Angina Pectoris; Humans; Immunoblastic Lymphadenopathy; Oxprenolol; Pancytopenia; Prednisone; Primar	1985
[Splenectomy, androgens and corticosteroids in the therapy of myelofibrosis. Description of 2 clinical cases]. Minerva medica, 1966, Sep-01, Volume: 57, Issue:70 Topics: Adrenocorticotropic Hormone; Adult; Female; Fluoxymesterone; Humans; Middle Aged; Prednisone; Primar	1966
[A case of lymphoid myelofibrosis. Anatomo-clinical and critical study]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1967, Dec-20, Volume: 43, Issue:53 Topics: Adult; Chlorambucil; Diagnosis, Differential; Humans; Leukemia; Male; Prednisone; Primary Myelofibro	1967
Pyoderma gangrenosum with myelofibrosis. The Journal of the Kentucky Medical Association, 1974, Volume: 72, Issue:10 Topics: Humans; Male; Middle Aged; Polycythemia Vera; Prednisone; Primary Myelofibrosis; Pyoderma; Pyridines	1974
Reversal of myelofibrosis in Hodgkin disease. JAMA, 1973, Mar-05, Volume: 223, Issue:10 Topics: Adult; Anemia, Aplastic; Biopsy, Needle; Cyclophosphamide; Female; Hodgkin Disease; Humans; Predniso	1973
Acute megakaryocytic myelofibrosis. Case report of an unusual myeloproliferative syndrome. American journal of clinical pathology, 1974, Volume: 62, Issue:1 Topics: Acute Disease; Adrenal Gland Neoplasms; Autopsy; Bone Marrow; Bone Marrow Cells; Busulfan; Female; H	1974
Myelofibrosis with unusual neurologic abnormalities. The American journal of medicine, 1971, Volume: 51, Issue:6 Topics: Aged; Ampicillin; Anemia; Blood Platelet Disorders; Bone and Bones; Brain; Dyspnea; Female; Heart; H	1971
Myelofibrosis and myeloid leukaemia. Acta paediatrica Scandinavica, 1967, Volume: 56, Issue:4 Topics: Anemia; Biopsy; Blood Transfusion; Child, Preschool; Erythrocyte Count; Hepatomegaly; Humans; Leukem	1967
Treatment of AGL. Archives of internal medicine, 1969, Volume: 123, Issue:2 Topics: Adult; Afibrinogenemia; Aged; Anemia; Antineoplastic Agents; Child; Cytarabine; Daunorubicin; Humans	1969
Agnogenic myeloid metaplasia; its current managment. Minnesota medicine, 1970, Volume: 53, Issue:3 Topics: Anemia; Female; Fluoxymesterone; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Splen	1970
Paroxysmal nocturnal haemoglobinuria. A clinical study. Acta medica Scandinavica, 1968, Volume: 184, Issue:6 Topics: Acetylcholinesterase; Adult; Aged; Anemia, Aplastic; Anemia, Hemolytic; Blood Cell Count; Blood Coag	1968
Abnormal (marker) chromosomes in two patients with acute myelofibrosis. Archives of internal medicine, 1969, Volume: 123, Issue:2 Topics: Aged; Anemia; Anti-Bacterial Agents; Blood Cell Count; Blood Cells; Blood Chemical Analysis; Blood T	1969
Coombs' positive hemolytic anemia in myelofibrosis with myeloid metaplasia. The American journal of the medical sciences, 1969, Volume: 258, Issue:2 Topics: Adult; Anemia, Hemolytic, Autoimmune; Busulfan; Coombs Test; Female; Humans; Male; Middle Aged; Pred	1969

prednisone and Agnogenic Myeloid Metaplasia